Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before–after trial
Sign Up to like & getrecommendations! Published in 2022 at "Lupus"
DOI: 10.1177/09612033221097812
Abstract: Objective To observe the efficacy and safety of telitacicept in refractory childhood-onset systemic lupus erythematosus (cSLE). Methods A self-controlled before–after trial. Children with active SLE, aged 5–18 years, who cannot tolerate side effects of glucocorticoid,… read more here.
Keywords: telitacicept refractory; refractory childhood; efficacy; childhood onset ... See more keywords